Fortress Biotech Inc (NASDAQ:FBIO)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting 1.66. At the close of trading, the stock’s price was $1.87, to imply a decrease of -2.09% or -$0.04 in intraday trading. The FBIO share’s 52-week high remains $2.89, putting it -54.55% down since that peak but still an impressive 27.27% since price per share fell to its 52-week low of $1.36. The company has a valuation of $51.63M, with an average of 0.59 million shares in intraday trading volume over the past 10 days and average of 655.32K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Fortress Biotech Inc (FBIO), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give FBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 1 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.75.
Fortress Biotech Inc (NASDAQ:FBIO) trade information
After registering a -2.09% downside in the last session, Fortress Biotech Inc (FBIO) has traded red over the past five days. The 5-day price performance for the stock is -7.88%, and 1.08% over 30 days. With these gigs, the year-to-date price performance is -7.65%. Short interest in Fortress Biotech Inc (NASDAQ:FBIO) saw shorts transact 2.62 million shares and set a 4.57 days time to cover.
Fortress Biotech Inc (FBIO) estimates and forecasts
Looking at statistics comparing Fortress Biotech Inc share performance against respective industry, we note that the company has outperformed competitors. Fortress Biotech Inc (FBIO) shares are -11.37% down over the last 6 months, with its year-to-date growth rate higher than industry average at 61.28% against 16.60%. The rating firms project that company’s revenue will shrink -31.22% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 15.58M.
FBIO Dividends
Fortress Biotech Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Fortress Biotech Inc insiders hold 21.21% of total outstanding shares, with institutional holders owning 15.78% of the shares at 20.03% float percentage. In total, 15.78% institutions holds shares in the company, led by B. RILEY WEALTH ADVISORS, INC..
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Fortress Biotech Inc (FBIO) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 470.54 shares. This is just over 1.70% of the total shares, with a market valuation of $0.88 million. Data from the same date shows that the other fund manager holds a little less at 152.47, or 0.55% of the shares, all valued at about 0.29 million.
